vs
Side-by-side financial comparison of Sachem Capital Corp. (SACH) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $12.0M, roughly 1.7× Sachem Capital Corp.). Sachem Capital Corp. runs the higher net margin — 8.3% vs -20.4%, a 28.7% gap on every dollar of revenue. On growth, Sight Sciences, Inc. posted the faster year-over-year revenue change (6.9% vs -18.8%). Over the past eight quarters, Sight Sciences, Inc.'s revenue compounded faster (2.9% CAGR vs -13.4%).
Sachem Capital Corp.SACHEarnings & Financial Report
Sachem Head Capital Management is an American value-oriented investment management firm based in New York City, managed by Scott Ferguson.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
SACH vs SGHT — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.0M | $20.4M |
| Net Profit | $997.0K | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | -3.1% | -18.0% |
| Net Margin | 8.3% | -20.4% |
| Revenue YoY | -18.8% | 6.9% |
| Net Profit YoY | 119.7% | 64.9% |
| EPS (diluted) | $0.00 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $20.4M | ||
| Q3 25 | $12.0M | $19.9M | ||
| Q2 25 | $10.8M | $19.6M | ||
| Q1 25 | $11.4M | $17.5M | ||
| Q4 24 | $10.8M | $19.1M | ||
| Q3 24 | $14.8M | $20.2M | ||
| Q2 24 | $15.1M | $21.4M | ||
| Q1 24 | $16.8M | $19.3M |
| Q4 25 | — | $-4.2M | ||
| Q3 25 | $997.0K | $-8.2M | ||
| Q2 25 | $1.9M | $-11.9M | ||
| Q1 25 | $904.0K | $-14.2M | ||
| Q4 24 | $-36.1M | $-11.8M | ||
| Q3 24 | $-5.1M | $-11.1M | ||
| Q2 24 | $-3.1M | $-12.3M | ||
| Q1 24 | $4.7M | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | — | -18.0% | ||
| Q3 25 | -3.1% | -39.7% | ||
| Q2 25 | 9.9% | -59.6% | ||
| Q1 25 | 9.0% | -79.2% | ||
| Q4 24 | -131.1% | -62.5% | ||
| Q3 24 | -32.6% | -55.7% | ||
| Q2 24 | -20.6% | -59.2% | ||
| Q1 24 | 25.4% | -76.4% |
| Q4 25 | — | -20.4% | ||
| Q3 25 | 8.3% | -41.0% | ||
| Q2 25 | 17.5% | -61.0% | ||
| Q1 25 | 7.9% | -80.8% | ||
| Q4 24 | -335.6% | -62.1% | ||
| Q3 24 | -34.2% | -54.9% | ||
| Q2 24 | -20.2% | -57.7% | ||
| Q1 24 | 27.8% | -84.4% |
| Q4 25 | — | $-0.07 | ||
| Q3 25 | $0.00 | $-0.16 | ||
| Q2 25 | $0.02 | $-0.23 | ||
| Q1 25 | $0.00 | $-0.28 | ||
| Q4 24 | $-0.79 | $-0.23 | ||
| Q3 24 | $-0.13 | $-0.22 | ||
| Q2 24 | $-0.09 | $-0.25 | ||
| Q1 24 | $0.08 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.6M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $175.6M | $63.9M |
| Total Assets | $484.4M | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $92.0M | ||
| Q3 25 | $12.6M | $92.4M | ||
| Q2 25 | $23.5M | $101.5M | ||
| Q1 25 | $25.8M | $108.8M | ||
| Q4 24 | $19.6M | $120.4M | ||
| Q3 24 | $7.4M | $118.6M | ||
| Q2 24 | $12.4M | $118.2M | ||
| Q1 24 | $56.8M | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | $230.2M | $42.4M | ||
| Q4 24 | $230.2M | $40.0M | ||
| Q3 24 | $264.7M | $37.1M | ||
| Q2 24 | $264.7M | $35.0M | ||
| Q1 24 | $288.4M | $35.0M |
| Q4 25 | — | $63.9M | ||
| Q3 25 | $175.6M | $64.3M | ||
| Q2 25 | $177.9M | $70.0M | ||
| Q1 25 | $179.3M | $77.6M | ||
| Q4 24 | $181.7M | $87.5M | ||
| Q3 24 | $220.6M | $95.0M | ||
| Q2 24 | $230.2M | $101.6M | ||
| Q1 24 | $237.4M | $109.2M |
| Q4 25 | — | $115.3M | ||
| Q3 25 | $484.4M | $116.3M | ||
| Q2 25 | $501.8M | $122.0M | ||
| Q1 25 | $491.4M | $129.7M | ||
| Q4 24 | $492.0M | $142.8M | ||
| Q3 24 | $555.5M | $143.6M | ||
| Q2 24 | $586.3M | $149.7M | ||
| Q1 24 | $626.5M | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | 1.28× | 0.55× | ||
| Q4 24 | 1.27× | 0.46× | ||
| Q3 24 | 1.20× | 0.39× | ||
| Q2 24 | 1.15× | 0.34× | ||
| Q1 24 | 1.21× | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.9M | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | 4.95× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.8M | ||
| Q3 25 | $4.9M | $-8.7M | ||
| Q2 25 | $501.0K | $-7.5M | ||
| Q1 25 | $191.0K | $-11.6M | ||
| Q4 24 | $12.9M | $-3.5M | ||
| Q3 24 | $2.3M | $362.0K | ||
| Q2 24 | $7.0M | $-9.5M | ||
| Q1 24 | $4.2M | $-9.8M |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | — | $-9.5M | ||
| Q1 24 | — | $-9.9M |
| Q4 25 | — | -9.7% | ||
| Q3 25 | — | -44.7% | ||
| Q2 25 | — | -39.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -18.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | -44.7% | ||
| Q1 24 | — | -51.4% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | 4.95× | — | ||
| Q2 25 | 0.27× | — | ||
| Q1 25 | 0.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.90× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SACH
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
